Description
Etilaam 1mg Tablet | Powerful Anxiety & Insomnia Treatment Guide
Etilaam 1mg Tablet contains etizolam, a thienodiazepine medication with properties similar to those of benzodiazepines. It is used for the management of anxiety and the short-term treatment of insomnia, or difficulty sleeping. Etizolam has anxiolytic, sedative, anticonvulsant, amnesic, and skeletal muscle relaxant properties.
Etilaam 1mg Tablet works by acting on benzodiazepine receptors in the central nervous system. Through this activity, etizolam can produce calming and sedative effects that may help reduce anxiety and support sleep. Because it affects the nervous system, the medication should be used according to the directions provided by a qualified healthcare professional.
Etizolam is a thienotriazolodiazepine, a class of compounds related to benzodiazepines. Its chemical structure differs from traditional benzodiazepines because its benzene ring is replaced by a thiophene ring and a fused triazole ring. These structural characteristics place etizolam within the thienotriazolodiazepine group.
After oral administration, Etilaam 1mg Tablet is absorbed relatively quickly. According to the provided pharmacological information, peak plasma concentrations of etizolam may be reached approximately 30 minutes to 2 hours after administration. Its average elimination half-life is approximately 3.5 hours, although individual responses can vary.
Etizolam has sedative and hypnotic properties and may reduce the time required to fall asleep, increase total sleep time, and reduce the number of nighttime awakenings. It may also influence sleep architecture, including reducing the amount of REM sleep. The medication’s effects and tolerability can vary between individuals.
The primary human metabolites of etizolam include alpha-hydroxyetizolam and 8-hydroxyetizolam. Alpha-hydroxyetizolam is pharmacologically active and has a reported half-life of approximately 8.2 hours.
Because Etilaam 1mg Tablet acts on the central nervous system and has sedative properties, it should be used carefully and only as directed. Patients should follow their prescribed dose and treatment duration and discuss any concerns about drowsiness, dependence, interactions, or prolonged use with their healthcare professional.
Etizolam was first patented in 1972 and received approval for clinical use in 1983. It has since been marketed under several brand names in different countries.
